Completed OBSERVATIONAL NCT06771674

Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma

Real-world Study of Patients With Human Papillomavirus-positive Recurrent/ Metastatic Oropharyngeal Squamous Cell Carcinoma Treated With First Line Pembrolizumab or Nivolumab With or Without Chemotherapy

Sponsor: Cardinal Health

Conditions Oropharyngeal Squamous Cell Carcinoma

Interventions Nivolumab Pembrolizumab

Updated 4 times since 2025 Last updated: Sep 8, 2025 Started: Jun 5, 2024 Primary completion: Feb 28, 2025 Completion: Feb 28, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06771674, this observational or N/A phase trial focuses on Oropharyngeal Squamous Cell Carcinoma and remains completed. Sponsored by Cardinal Health, it has been updated 4 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Oct 2025 — Present [monthly]

Completed

Status: Active Not Recruiting → Completed
Apr 2025 — Oct 2025 [monthly]

Active Not Recruiting
Mar 2025 — Apr 2025 [monthly]

Active Not Recruiting
Feb 2025 — Mar 2025 [monthly]

Active Not Recruiting

First recorded

Jun 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cardinal Health
Hookipa Biotech GmbH

Data source: Hookipa Biotech GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dublin, United States